Octapharma USA announced that the FDA has approved Octagam 10% [Immune Globulin Intravenous (Human)] liquid preparation for the treatment of adults with chronic immune thrombocytopenic purpura (ITP).

Octagam 10% is a solvent/detergent treated, sterile preparation of highly purified immunoglobulin G (IgG) derived from large pools of human plasma.

The approval of Octagam 10% is based on the results of an Octapharma-sponsored clinical trial to evaluate the safety and efficacy of Octagam 10% in 66 patients ages 17–88 years old with chronic ITP.

RELATED: Immune Disorders Resource Center

Octagam 10% will be supplied in 2g, 5g, 10g, and 20g single-use bottles. Octagam 10% will be available in September 2014.

For more information call (888) 429-4535 or visit Octapharma.com.